Medicsight Plc (AIM: MDST), industry leader in the development of Computer-Aided Detection (CAD) and image analysis software which assists in the early detection and diagnosis of disease, today announces a number of recent developments that have occurred surrounding the Company's recent admission to the AIM market.

Regulatory approvals

On 4 June Medicsight CE marked MedicRead Colon 1.0 and ColonCAD™ API 3.2. CE marking indicates conformity with the essential safety requirements set out in the European Medical Device Directives.

On 5 July Medicsight was granted medical device licences from the Therapeutic Products Directorate of Health Canada to begin marketing and selling Medicsight MedicRead Colon 1.0 in Canada.

Commercial Partnerships

Medicsight distributes its products through partnerships with some of the leading 3D visualisation equipment manufacturers. Medicsight has recently reinforced its global distribution capability and relationships with three key partners, Vital Images Inc., Viatronix Inc., and TeraRecon Inc, and in addition signed a new global contract with Barco N.V.

The Viatronix global contracts have been re-signed to improve commercial terms and practical business arrangements.

The new global contract signed with Barco, a leading provider of enterprise-wide 3D advanced visualization solutions, will enable Medicsight's ColonCAD™ image analysis software tools to be distributed with Barco's 3D visualization products and through the Picture Archiving and Communication Systems (PACS) offered by Barco's partners.

These contracts will allow Medicsight and its current partners to accelerate penetration into the growing CAD market. The total installed base opportunity of these Medicsight partners is over 7,500 CT workstations & licences.

Conference participation

Medicsight has showcased its CAD software at the following radiology conferences this year:

• 9-13 March 2007, Professor Steve Halligan of University College Hospital, London, and Dr. David Burling of St. Mark's Hospital, London gave presentations on Medicsight CAD technology at the European Congress of Radiology, Vienna
• 13-15 April 2007, Medicsight and Toshiba co-sponsored the first CT Colonography training workshop at the Japan Radiological Society in Yokohama, Japan
• 12-15 June Professor Steve Halligan, Dr Stuart Taylor of University College Hospital, London and Dr. David Burling gave presentations on Medicsight CAD technology at the European Society of Gastrointestinal and Abdominal Radiology, Lisbon

David Sumner, CEO of Medicsight, commented "We're delighted to have achieved these significant milestones during and since our successful debut on the AIM market. These are of particular value as we continue to successfully market our innovative world leading CAD software with partners across all global markets."

For further information:
Medicsight plc

David Sumner
+44 (0)20 7605 7950
www.medicsight.com

Collins Stewart Europe Limited
Tim Mickley
+44 (0)20 7523 8350
Jonny Sloan
+44 (0)20 7523 8302

Media enquiries:
Abchurch
Ashley Tapp
Tel: +44 (0) 20 7398 7700
Mob: +44 (0) 7944 570 387
ashley.tapp@abchurch-group.com

Stephanie Cuthbert
Tel: +44 (0) 20 7398 7700
Mob: +44 (0) 7843 080947
stephanie.cuthbert@abchurch-group.com
www.abchurch-group.com

Notes to editors

Medicsight PLC is a UK-based, research driven, leading developer of computer-aided detection (CAD) and image analysis software for the medical imaging market. The CAD software automatically highlights suspicious areas on computerised tomography (CT) scans of the colon and lung, helping radiologists to identify, measure and analyse potential disease and early indicators of disease. Medicsight's CAD software has been validated using one of the world's largest and most population diverse databases of verified patient CT scan data. Medicsight's ColonCAD™ and LungCAD™ software products are seamlessly integrated with the advanced 3D visualisation workstations of several industry-leading imaging equipment partners.

About Computer-Aided Detection

With increasingly sophisticated radiological imaging hardware such as Multi-Detector CT scanners, radiologists are facing a growing challenge in the amount of detailed patient image data that they must review for each patient examination. Some CT scan examinations generate as many as 1000 images per patient. Review of this data by the radiologist is not only time-consuming but also prone to error due to reader fatigue. CAD software can help the reviewing radiologist by analysing the image data and automatically highlighting suspicious regions of interest for closer inspection. Without CAD software some potential abnormalities or areas of disease may be overlooked. This is critical for diagnosis and the management of patient outcomes as early detection of disease greatly increases the probability of successful treatment and a positive therapeutic outcome.

About Medicsight's CAD software

Medicsight's ColonCAD™ and LungCAD™ software use an advanced CAD algorithm to analyse CT scans of the colon and lung and automatically highlight suspicious areas that may be indicators of disease. CAD may highlight areas easily overlooked by the reviewing radiologist, such as small lesions or regions that are hidden from view behind folds in the colon or normal structures and surrounding tissue in the lung.

Both CAD products seamlessly integrate with the advanced 3D visualisation platforms of industry-leading imaging equipment partners. The integrated systems provide sophisticated image viewing capabilities, including 3D reconstructed image data, with the added advantage of demonstrating automatic CAD findings to assist clinical end users in the detection and analysis of disease. This allows clinical end users to perform either a 'second read', where CAD findings are displayed to the user after completion of an initial review of the CT scan data, or a 'concurrent read' where CAD findings are displayed during the user's initial review of the original CT scan images.

Since inception, Medicsight has developed close and lasting relationships with some of the world's foremost clinicians in product related areas. This provides the Company with a wealth of clinical expertise and dedicated clinical research to support ongoing product development. Medicsight also collaborates with a number of leading academic institutions and clinical research programmes worldwide to develop the Company's comprehensive database of population diverse verified patient CT scan data, thus allowing Medicsight's products to be validated to the highest possible standards.